Clinical trials
Completed Cataract trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
885 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 4 |
| 2001 | 3 |
| 2002 | 5 |
| 2003 | 4 |
| 2004 | 13 |
| 2005 | 17 |
| 2006 | 22 |
| 2007 | 30 |
| 2008 | 33 |
| 2009 | 44 |
| 2010 | 37 |
| 2011 | 38 |
| 2012 | 38 |
| 2013 | 33 |
| 2014 | 48 |
| 2015 | 37 |
| 2016 | 38 |
| 2017 | 46 |
| 2018 | 61 |
| 2019 | 42 |
| 2020 | 54 |
| 2021 | 58 |
| 2022 | 56 |
| 2023 | 49 |
| 2024 | 32 |
| 2025 | 17 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 885 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alcon Research | 94 |
| Bausch & Lomb Incorporated | 32 |
| Beaver-Visitec International, Inc. | 32 |
| Sun Yat-sen University | 24 |
| Johnson & Johnson Surgical Vision, Inc. | 23 |
| National Eye Institute (NEI) | 21 |
| Medical University of Vienna | 17 |
| Abbott Medical Optics | 16 |
| Democritus University of Thrace | 14 |
| Carl Zeiss Meditec AG | 10 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cataract | 885 |
| Astigmatism | 60 |
| Presbyopia | 55 |
| Glaucoma | 40 |
| Aphakia | 34 |
| Inflammation | 28 |
| Glaucoma, Open-Angle | 22 |
| Pain | 17 |
| Pseudophakia | 16 |
| Macular Edema | 15 |
Trials
Showing 1 to 25 of 885. Each trial links to its page on Pharma Observatory.
785 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.